

**Critical Care Guidelines  
FOR CRITICAL CARE USE ONLY**

**Nimodipine**

**PRESENTATION:** Vials containing nimodipine 10mg in 50mls

**INDICATION:** Treatment of ischaemic neurological deficits following aneurysmal subarachnoid haemorrhage.

**DOSE AND ADMINISTRATION:**

**ICU STANDARD INFUSION**

**Bodyweight greater than or equal to 70kg:**

The recommended rate for the first two hours is 1mg/hr (5ml/hr); after two hours increase to 2mg/hr (10ml/hr); providing no clinically significant decrease in blood pressure is observed.

**Bodyweight less than 70kg or with unstable blood pressure:**

The patient should be started on a dose of 500micrograms/hr (2.5ml/hr) or less if necessary.

Nimodipine should be administered via a central venous catheter.

**ADMINISTRATION:**

Nimodipine should be withdrawn from the vial into a 50ml syringe and connected to a three-way stopcock using the infusion line provided. The three-way stopcock should be used to connect the Nimotop polyethylene tube with the co-infusion line and the central catheter.

Nimodipine MUST be administered in conjunction with a co-infusion due to high ethanol content increasing risk of irritation. This should be connected to the second port on the three-way stopcock.

The co-infusion should be sodium chloride 0.9% or glucose 5% in a ratio of about 1:4 (nimodipine: co-infusion – see table below).

Dose	0.5 mg/hour	1 mg/hour	2 mg/hour
Nimodipine infusion rate	2.5 mL/hour	5 mL/hour	10 mL/hour
Fluid co-infusion rate	10 mL/hour	20 mL/hour	40 mL/hour

Nimodipine must NOT be added to an infusion bag or bottle and must not be mixed with other drugs.

**CONCENTRATION:** 200micrograms/ml (10mg in 50ml)

**STABILITY:** Protect from direct sunlight. Stable for 10 hours.

**References:**

1. Summary of Product Characteristics, Nimotop 0.02% Solution for Infusion, Bayer plc. <https://www.medicines.org.uk/emc/product/1366/smpc#gref> . Accessed 18/04/2023.
2. Medusa, NHS Injectable Medicines Guide. Published 15/12/22. Accessed 18/04/2023.

Critical Care Guidelines: Nimodipine	
Authors: Claire Hannah	
Document Version: 3.0	Authoriser: Lothian Critical Care Directorate QIT Editorial Board
Authorisation Date: April 2023	Review Date: April 2025